000168951 001__ 168951
000168951 005__ 20251118111811.0
000168951 0247_ $$2doi$$a10.1080/2162402X.2021.1920739
000168951 0247_ $$2pmid$$apmid:34026332
000168951 0247_ $$2pmc$$apmc:PMC8128181
000168951 0247_ $$2ISSN$$a2162-4011
000168951 0247_ $$2ISSN$$a2162-402X
000168951 0247_ $$2altmetric$$aaltmetric:106370847
000168951 037__ $$aDKFZ-2021-01153
000168951 041__ $$aEnglish
000168951 082__ $$a610
000168951 1001_ $$0P:(DE-He78)0d76712a960555ea778f5b7f35334414$$aZhang, Xin-Wen$$b0$$eFirst author$$udkfz
000168951 245__ $$aActivity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma.
000168951 260__ $$aAbingdon$$bTaylor & Franics$$c2021
000168951 3367_ $$2DRIVER$$aarticle
000168951 3367_ $$2DataCite$$aOutput Types/Journal article
000168951 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763461080_1939187
000168951 3367_ $$2BibTeX$$aARTICLE
000168951 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168951 3367_ $$00$$2EndNote$$aJournal Article
000168951 500__ $$a#EA:D170#LA:D170# / #DKFZ-MOST-Ca188#
000168951 520__ $$aDendritic cell (DC) vaccination has proven to be an effective and safe adjuvant for cancer immunotherapies. As the presence of DCs within the tumor microenvironment promotes adaptive antitumor immunity, enhancement of DC migration toward the tumor microenvironment following DC vaccination might represent one possible approach to increase its therapeutic efficacy. While recent findings suggest the activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) as critical regulator of DC migration in the context of autoimmune diseases, we aimed to investigate the impact of Arc/Arg3.1 expression for DC-based cancer vaccines. To this end, DC migration capacity as well as the induction of T cell-mediated antitumor immunity was assessed in an experimental B16 melanoma model with Arc/Arg3.1-/- and Arc/Arg3.1-expressing BMDCs applied as a subcutaneous vaccine. While antigen presentation on DCs was critical for unleashing effective T cell mediated antitumor immune responses, Arc/Arg3.1 expression enhanced DC migration toward the tumor and secondary lymphoid organs. Moreover, Arc/Arg3.1-expressing BMDCs shape the tumor immune microenvironment by facilitating tumor recruitment of antigen-specific effector T cells. Thus, Arc/Arg3.1 may represent a novel therapeutic target in DCs in order to increase the therapeutic efficacy of DC vaccination.
000168951 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000168951 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168951 650_7 $$2Other$$aAdoptive immunotherapy
000168951 650_7 $$2Other$$aCD8-positive T-lymphocytes
000168951 650_7 $$2Other$$adendritic cells
000168951 650_7 $$2Other$$amelanoma
000168951 650_7 $$2Other$$atumor microenvironment
000168951 7001_ $$0P:(DE-He78)7ff2c04c9c3a7723806c97a832e47918$$aHuck, Katrin$$b1$$udkfz
000168951 7001_ $$0P:(DE-He78)106aed16a97ff393cca5528582f8c655$$aJähne, Kristine$$b2$$udkfz
000168951 7001_ $$0P:(DE-He78)7c69c3cf30a54f9f06e15af48f62ce3c$$aCichon, Frederik$$b3$$udkfz
000168951 7001_ $$0P:(DE-He78)1f1efec9a95d1778031cb6f0b19ba58b$$aSonner, Jana$$b4
000168951 7001_ $$aUfer, Friederike$$b5
000168951 7001_ $$aBauer, Simone$$b6
000168951 7001_ $$aWoo, Marcel Seungsu$$b7
000168951 7001_ $$0P:(DE-He78)9b97ca569bcb00dfda69382bc7261700$$aGreen, Ed$$b8$$udkfz
000168951 7001_ $$0P:(DE-He78)88073210769f9ba0da4cf6b7d6c044f8$$aLu, Kevin$$b9$$udkfz
000168951 7001_ $$0P:(DE-He78)bed62b0b74cf1048663fbefeb4b5d7bc$$aKilian, Michael$$b10$$udkfz
000168951 7001_ $$aFriese, Manuel A$$b11
000168951 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b12$$udkfz
000168951 7001_ $$0P:(DE-He78)0f9fbf5fd70dad2bba0760cee65c9613$$aSahm, Katharina$$b13$$eLast author$$udkfz
000168951 773__ $$0PERI:(DE-600)2645309-5$$a10.1080/2162402X.2021.1920739$$gVol. 10, no. 1, p. 1920739 -$$n1$$p1920739$$tOncoImmunology$$v10$$x2162-402X$$y2021
000168951 909CO $$ooai:inrepo02.dkfz.de:168951$$pVDB
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0d76712a960555ea778f5b7f35334414$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ff2c04c9c3a7723806c97a832e47918$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)106aed16a97ff393cca5528582f8c655$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7c69c3cf30a54f9f06e15af48f62ce3c$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1f1efec9a95d1778031cb6f0b19ba58b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b97ca569bcb00dfda69382bc7261700$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)88073210769f9ba0da4cf6b7d6c044f8$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bed62b0b74cf1048663fbefeb4b5d7bc$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000168951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f9fbf5fd70dad2bba0760cee65c9613$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000168951 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000168951 9130_ $$0G:(DE-HGF)POF3-314$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTumor immunology$$x0
000168951 9141_ $$y2021
000168951 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOIMMUNOLOGY : 2019$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-01-29
000168951 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOIMMUNOLOGY : 2019$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-29
000168951 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-29
000168951 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000168951 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000168951 980__ $$ajournal
000168951 980__ $$aVDB
000168951 980__ $$aI:(DE-He78)D170-20160331
000168951 980__ $$aI:(DE-He78)HD01-20160331
000168951 980__ $$aUNRESTRICTED